Medtronic (NYSE:MDT) TAVR System Shows Strong Five-Year Performance Despite 3% Price Dip

Medtronic (NYSE:MDT) recently saw a substantial price movement, climbing 10% over the last quarter. This period was marked by the release of promising five-year data from the Evolut Low Risk Trial, which indicated favorable outcomes for the company's transcatheter aortic valve replacement system compared to surgery. Further boosting investor sentiment was the FDA approval of Medtronic's BrainSense technology, enhancing treatment for Parkinson's disease. Despite challenging overall market conditions, with significant declines in key indexes such as the S&P 500 and Nasdaq, Medtronic's substantial product advancements likely contributed to the positive performance of its shares amidst broader downward trends.

Buy, Hold or Sell Medtronic? View our complete analysis and fair value estimate and you decide.

Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 20 best rare earth metal stocks of the very few that mine this essential strategic resource.

Over the past five years, Medtronic has delivered a total shareholder return of 7.52%. While this performance marks a modest increase, it underperforms both the broader U.S. market and the medical equipment industry over the last year, where market returns were 5.8% and industry returns were 2.4%, respectively. Several key developments likely influenced Medtronic’s share price trajectory during this period. The announcement of the global observational study DISSECT-N in June 2020 and the FDA approval for the Percept PC Deep Brain Stimulation system marked significant milestones. Furthermore, the launch and European release of the Evolut TAVR system in mid-2020 demonstrated Medtronic’s continued commitment to innovation.

The company's consistent dividend payouts bolstered investor confidence, with recent approvals maintaining shareholder value. Additionally, the approval and expansion of Medtronic's Renal Denervation technique and the ongoing development of the Hugo soft tissue robotic platform have shaped its growth narrative, targeting increased market share and revenue expansion, particularly in emerging markets. However, challenges such as competitive pressures and regulatory hurdles may have constrained faster growth in the valuation metrics. Collectively, these factors provide context to Medtronic's overall market performance over the past five years.

The analysis detailed in our Medtronic valuation report hints at an deflated share price compared to its estimated value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com